Bergamot Extract Clinical Trial 2024 Cholesterol Stuns Experts
- 01. What the 2024 trial found
- 02. Key numerical results
- 03. How the extract is thought to work
- 04. Practical interpretation for clinicians and patients
- 05. Study design snapshot (illustrative table)
- 06. Context: prior evidence and meta-analyses
- 07. Safety and adverse events
- 08. Regulatory and product notes
- 09. Representative quote from the research team
- 10. Limitations and open questions
- 11. Practical guidance for consumers
- 12. Quick reference: comparative numbers
- 13. Selected citations and sources
Short answer: A 2024 randomized, double-blind, placebo-controlled clinical trial of a standardized bergamot extract (Bergavit™) reported statistically significant reductions in low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) over a four-month treatment course-LDL-C fell about 11.5% and TC about 8.8% versus baseline-with the largest changes emerging at the three-to-four month marks (study published in Foods, November 2024).
What the 2024 trial found
The 2024 randomized, double-blind, placebo-controlled trial enrolled adults aged 40-70 with untreated dyslipidemia and gave 375 mg daily of a bergamot juice extract standardized to 150 mg flavonoids (neohesperidin, naringin, neoeriocitrin) or placebo for four months; the active group showed progressive LDL-C reductions of 7.2% at two months, 8.8% at three months and 11.5% at four months.
Key numerical results
The trial reported the following clinically relevant lipid changes in the active arm compared with baseline: total cholesterol -8.8% at four months, LDL-C -11.5% at four months, triglycerides reduction with mixed significance across checkpoints, and an equivocal HDL-C increase (significant at three months but borderline at month four).
- Trial population: 64 adults, ages 40-70, untreated dyslipidemia.
- Dose: 375 mg bergamot extract (150 mg standardized flavonoids) once daily.
- Duration: 4 months (measurements at 1, 2, 3, 4 months).
- Primary outcomes: Percent change in LDL-C and TC.
How the extract is thought to work
Bergamot flavonoids are proposed to increase hepatic LDL receptor activity and shift LDL particle distribution away from small, dense (more atherogenic) particles toward larger, less atherogenic subfractions-mechanisms that could explain observed LDL-C lowering in humans.
Practical interpretation for clinicians and patients
For adults with mild to moderate dyslipidemia who are either statin-intolerant or seeking adjunctive non-pharmacologic options, a standardized bergamot extract at the trial dose produced modest but measurable LDL-C reductions (~8-12% by month four), which compare to small-dose nutraceutical effects but are less than typical statin reductions (statins lower LDL-C by ~30-60% depending on intensity).
Study design snapshot (illustrative table)
| Feature | 2024 Foods Trial (illustrative) |
|---|---|
| Design | Randomized, double-blind, placebo-controlled, parallel groups. |
| Participants | 64 adults, untreated dyslipidemia, ages 40-70. |
| Intervention | 375 mg Bergavit™ (150 mg flavonoids) once daily for 4 months. |
| Primary outcome | Percent change in LDL-C and total cholesterol at 4 months. |
| Key result | LDL-C -11.5% at 4 months; TC -8.8% at 4 months. |
Context: prior evidence and meta-analyses
Systematic reviews and meta-analyses before and after 2020 reported heterogeneous but largely positive effects of bergamot supplementation on lipids, with some trials showing TC reductions from roughly 12% to 31% and LDL-C reductions from about 7% up to 41% depending on dose, formulation, and co-interventions; overall evidence quality varied and trial designs were heterogeneous.
- Heterogeneity in formulation: bergamot preparations differ in total flavonoid content and standardization, producing variable effects across trials.
- Population differences: some trials enrolled statin-naïve adults with mild dyslipidemia while others included overweight or metabolically at-risk individuals, altering absolute effect sizes.
- Combination products: several studies tested bergamot in multi-ingredient nutraceuticals (sterols, artichoke), complicating attribution to bergamot alone.
Safety and adverse events
The 2024 trial monitored hepatic and renal safety markers and reported no clinically meaningful safety signals over the four-month period; historically, bergamot extracts have been generally well tolerated in trials, but long-term safety data remain limited and herb-drug interactions (e.g., CYP enzyme effects) are plausible and under-studied.
Regulatory and product notes
Bergamot supplements are marketed as nutraceuticals/food supplements rather than pharmaceutical drugs in most jurisdictions; product label standardization (specific flavonoid content) is critical to reproduce clinical results because nonstandard extracts may deliver different active doses.
Representative quote from the research team
"There was a significant decrease in total cholesterol and LDL-C levels along with further results indicating that Bergavit is a natural way to manage healthy cholesterol levels," said Vincenzo Zaccaria, PhD, R&D manager for the extract manufacturer, in the study press release.
Limitations and open questions
Limitations of the 2024 study include modest sample size (n≈64), four-month follow-up which constrains long-term efficacy/safety conclusions, single-product testing limiting generalizability to other bergamot formulations, and variable HDL/triglyceride effects that require larger trials for confirmation.
Practical guidance for consumers
Consumers considering bergamot supplements should choose standardized products (label that lists flavonoid content), discuss use with their clinician-especially if taking statins or other cardiovascular drugs-and expect modest LDL-C reductions over several months rather than immediate large shifts in cholesterol.
Quick reference: comparative numbers
| Intervention | Typical LDL-C change | Notes |
|---|---|---|
| Bergamot extract (2024 trial) | -8-12% by month 4. | Standardized 150 mg flavonoids, 375 mg extract. |
| Low-intensity statin | ≈-20% to -30% | Pharmacologic standard; larger and faster LDL lowering. |
| Lifestyle (diet/exercise) | Variable, often modest single-digit % changes | Essential baseline therapy; additive with supplements. |
Selected citations and sources
The primary 2024 randomized trial was published in Foods (2024) under the title "Citrus bergamia Extract, a Natural Approach for Cholesterol and Lipid Metabolism Management," reporting detailed percent changes and study DOI information.
What are the most common questions about Bergamot Extract Clinical Trial 2024 Cholesterol Stuns Experts?
[Is bergamot an effective statin alternative]?
Bergamot produced meaningful LDL-C decreases in multiple studies but is not a full substitute for moderate- or high-intensity statin therapy for patients who require large LDL-C reductions; however, it may be useful as an adjunct or for patients with statin intolerance.
[What dose was tested]?
The 2024 Foods trial used 375 mg/day of Bergavit™ standardized to 150 mg flavonoids; other studies have used varying doses (for example, earlier trials used 120-500 mg/day preparations), so formulations and flavonoid content matter for replicating results.
[How quickly do results appear]?
In the 2024 trial, LDL-C reductions were measurable by two months and reached maximal observed effect around month four, with percent decreases increasing steadily across monthly checkpoints.
[Are the results clinically meaningful]?
Relative LDL-C drops of ~8-12% are clinically useful for risk reduction but smaller than statin therapy; combining bergamot with lifestyle measures or other evidence-based nutraceuticals may produce additive benefit for low- to moderate-risk patients.
[Are there known drug interactions]?
Bergamot contains bioactive flavonoids and furanocoumarin-like compounds that may affect drug-metabolizing enzymes and transporters; clinicians should exercise caution and review concomitant medications before recommending bergamot supplements.
[What research is still needed]?
Large multicenter randomized trials with diverse populations, head-to-head comparisons to low-dose statins, longer follow-up for cardiovascular outcomes, and mechanistic pharmacokinetic studies of active flavonoids and potential drug interactions are the key next steps.
[Should I take bergamot for high cholesterol]?
Speak with your clinician first; bergamot showed modest LDL-C reductions in randomized trials and may be appropriate as an adjunct or for statin-intolerant patients, but it should not replace guideline-recommended statin therapy for those with high cardiovascular risk.